Skip to content

The effect of Saccharomyces boulardii supplementation on the vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication

The effect of Saccharomyces boulardii supplementation on the vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075347
Enrollment
Unknown
Registered
2023-09-01
Start date
2023-09-01
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Sponsors

The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. 13C urea breath test or rapid urease test positive; 2. Aged 18-70 years old; 3. initial H. pylori eradication treatment recipients.

Exclusion criteria

Exclusion criteria: a) Allergies to the drugs used in this study b) Have a history of gastric surgery c) During the study period, PPI, antibiotics, and steroids should not be discontinued d) Pregnancy/lactation period e) Acute infection of mononucleosis f) Decompensation of heart, liver, kidney, and lung diseases g) Diagnosed or suspected upper gastrointestinal malignancy due to use of antibiotics within the first 4 weeks of the study and PPI or fumarasone within 2 weeks

Design outcomes

Primary

MeasureTime frame
Eradication rate;

Secondary

MeasureTime frame
Adverse events;Compliance;

Countries

China

Contacts

Public ContactXiaoyong Wang

The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University

wxy20009@126.com+86 137 7505 1593

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 26, 2026